Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 351

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 19
Chunk 351
---
 loss. Accordingly, the above amendment resulted in approximately $4.0 million of interest expense in the fourth quarter of 2024.

F - 32

BioLineRx Ltd.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 12 - EQUITY

  Share capital  

The Company’s share capital is composed of ordinary shares, as follows:

                                        Number of Ordinary Shares                                        
                                        December 31,                                                     
                                        2023                                                             
  Authorized share capital                                             2,500,000,000      5,000,000,000  
  Issued and paid-up share capital                                     1,086,589,165      1,336,670,575  

                                                 In USD and NIS Amounts                                    
                                                 December 31,                                              
                                                 2023                                                      
  Authorized share capital (in NIS)                                          250,000,000      500,000,000  
  Issued and paid-up share capital (in NIS)                                  108,658,916      133,667,057  
  Issued and paid-up share capital (in USD)                                  31,355,056       38,096,940   

  Rights related to shares  

The ordinary shares confer upon their holders voting and dividend rights and the right to receive assets of the Company upon its liquidation. As of December 31, 2023 and 2024, all outstanding share capital consisted of ordinary shares.

  Changes in the Company’s equity  
 ───────────────────────────────────

  In September 2022, the Company completed a registered direct offering of 340,909 ADSs at a price of $ 44.00 per ADS. The Company also issued to investors in the offering unregistered warrants t...  
  The warrants issued to the investors have been classified as a financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the issuance d...  
                                                                                                                                                                                                        
                                                                                                                                                                                                        
                                                                                                                                                                                                        
  The fair value of the warrants is computed using the Black-Scholes option pricing model. The fair value of the warrants upon issuance was computed based on the then-current price of an ADS, a r...  
                                                                                                                                                                                                        
                                                                                                                                                                                                        
                                                                                                                                                                                                        
  The fair value of the warrants amounted to $ 478,000 as of December 31, 2024 (December 31, 2023 - $ 11,905,000), and was based on the then current price of an ADS